Exhibit 99.1
AUG 2022
About this presentation This investor presentation (“Presentation”) contains proprietary and confidential information of Social Capital Suvretta Holdings Corp. I (“SCS”) and Akili Interactive Labs, Inc. (“Akili” or the “Company”), and the entire content should be considered “Confidential Information” with respect to both SCS and the Company. This presentation is made solely for informational purposes, and no representation or warranty, express or implied, is made by SCS, the Company or any of their representatives as to the information contained in these materials or disclosed during any related presentations or discussions. The recipient of this presentation shall keep this presentation and its contents confidential, shall not use this presentation and its contents for any purpose other than as expressly authorized by SCS and the Company and shall be required to return or destroy all copies of this presentation or portions thereof in its possession promptly following request for the return or destruction of such copies. By accepting delivery of this presentation, the recipient is deemed to agree to the foregoing confidentiality requirements. This Presentation is for informational purposes only to assist interested parties in making their own evaluation with respect to the proposed business combination (the “Business Combination”) between SCS and the Company and related transactions and for no other purpose. No representations or warranties, express or implied are given in, or in respect of, this presentation. To the fullest extent permitted by law in no circumstances will SCS, the Company, Morgan Stanley & Co. LLC, Credit Suisse Securities (USA) LLC and Cowen & Company, LLC, nor any of their respective subsidiaries, stockholders, affiliates, representatives, partners, directors, officers, employees, investment banks, advisers or agents be responsible or liable for any direct, indirect or consequential loss or loss of profit arising from the use of this presentation, its contents, its omissions, reliance on the information contained within it, or on opinions communicated in relation thereto or otherwise arising in connection therewith. Industry and market data used in this presentation have been obtained from third-party industry publications and sources as well as from research reports prepared for other purposes. Neither SCS nor the Company has independently verified the data obtained from these sources and cannot assure you of the data’s accuracy or completeness. This data is subject to change. In addition, this presentation does not purport to be all-inclusive or to contain all of the information that may be required to make a full analysis of the Company or the Business Combination. Viewers of this presentation should each make their own evaluation of the Company and of the relevance and adequacy of the information and should make such other investigations as they deem necessary. This Presentation and the information contained herein do not constitute (i) (a) a solicitation of a proxy, consent or authorization with respect to any securities or in respect of the proposed Business Combination or (b) an offer to sell or the solicitation of an offer to buy any security, commodity or instrument or related derivative, nor shall there be any sale of securities in any jurisdiction in which the offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction, or (ii) an offer or commitment to lend, syndicate or arrange a financing, underwrite or purchase or act as an agent or advisor or in any other capacity with respect to any transaction, or commit capital, or to participate in any trading strategies. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, or an exemption therefrom. FORWARD LOOKING STATEMENTS Certain statements, estimates, targets and projections in this Presentation may be considered forward-looking statements within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or involving, or future performance of, SCS or the Company. For example, statements concerning the following include forward-looking statements: projections of the Company’s future financial results and other metrics, the satisfaction of closing conditions to the Business Combination and the timing of the completion of the Business Combination; the growth of the Company’s business and its ability to realize expected results; the Company’s plans for commercialization of EndeavorRx®; the growth and expansion of its clinical development pipeline; the viability of its growth and commercialization strategy, including related capabilities; trends and developments in the digital healthcare industry; the advantages and potential of its solution; its visibility into future financial performance; and the total addressable markets for the Company’s development candidates. In some cases, you can identify forward-looking statements by terminology such as “pro forma”, “may”, “should”, “expect”, “intend”, “will”, “estimate”, “anticipate”, “believe”, “predict”, “potential” or “continue”, or the negatives of these terms or variations of them or similar terminology. Forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by SCS and its management, and the Company and its management, as the case may be, are inherently uncertain. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: the occurrence of any event, change or other circumstances that could give rise to the termination of negotiations and any subsequent definitive agreements with respect to the Business Combination; the outcome of any legal proceedings that may be instituted against SCS, the Company, the combined company or others following the announcement of the Business Combination and any definitive agreements with respect thereto; the inability to complete the Business Combination due to the failure to obtain approval of the stockholders of SCS, or the Company to obtain financing to complete the Business Combination or to satisfy other conditions to closing; changes to the proposed structure of the Business Combination that may be required or appropriate as a result of applicable laws or regulations or as a condition to obtaining regulatory approval of the Business Combination; the ability to meet stock exchange listing standards following the consummation of the Business Combination; the risk that the Business Combination disrupts current plans and operations of the Company as a result of the announcement and consummation of the Business Combination; the ability to recognize the anticipated benefits of the Business Combination, which may be affected by, among other things, competition, the ability of the combined company to grow and manage growth profitably, maintain relationships with customers and suppliers and retain its management and key employees; costs related to the Business Combination; changes in applicable laws or regulations; the possibility that the Company or the combined company may be adversely affected by other economic, business, regulatory, and/or competitive factors; the Company’s estimates of expenses and profitability; the evolution of the markets in which the Company competes; the ability of the Company to implement its strategic initiatives and continue to innovate its existing products; the ability of the Company to defend its intellectual property and satisfy regulatory requirements; the impact of the COVID-19 pandemic on the Company’s business; and other risks and uncertainties set forth in the section entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in SCS’s final prospectus dated June 29, 2021 relating to its initial public offering and other risks and uncertainties indicated from time to time in the definitive proxy statement delivered to SCS’s stockholders and related registration statement on Form S-4, including those set forth under “Risk Factors” therein, and other documents filed or to be filed with the Securities and Exchange Commission (the “SEC”) by SCS. 2
About this presentation FORWARD LOOKING STATEMENTS Certain statements, estimates, targets and projections in this investor presentation may be considered forward-looking statements within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or involving, or future performance of Akili, Inc. (the “Company”). For example, statements concerning the following include forward-looking statements: projections of the Company’s future financial results and other metrics’ the growth of the Company’s business and its ability to realize expected results; the Company’s plans for commercialization of EndeavorRx®; the growth and expansion of its clinical development pipeline; the viability of its growth and commercialization strategy, including related capabilities; trends and developments in the digital healthcare industry; the advantages and potential of its solution; its visibility into future financial performance; and the total addressable markets for the Company’s development candidates. In some cases, you can identify forward-looking statements by terminology such as “pro forma”, “may”, “should”, “expect”, “intend”, “will”, “estimate”, “anticipate”, “believe”, “predict”, “potential” or “continue”, or the negatives of these terms or variations of them or similar terminology. Forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by the Company and its management are inherently uncertain. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: the outcome of any legal proceedings that may be instituted against he Company or others following the announcement of the business combination and any definitive agreements with respect thereto; the ability to maintain stock exchange listing standards following the consummation of the business combination; the risk that the business combination disrupts current plans and operations of the Company as a result of the announcement and consummation of the business combination; the ability to recognize the anticipated benefits of the business combination, which may be affected by, among other things, competition, the ability of the combined company to grow and manage growth profitably, maintain relationships with customers and suppliers and retain its management and key employees; costs related to the business combination; changes in applicable laws or regulations; the possibility that the Company or the combined company may be adversely affected by other economic, business, regulatory, and/or competitive factors; the Company’s estimates of expenses and profitability; the evolution of the markets in which the Company competes; the ability of the Company to implement its strategic initiatives and continue to innovate its existing products; the ability of the Company to defend its intellectual property and satisfy regulatory requirements; the impact of the COVID-19 pandemic on the Company’s business; and other risks and uncertainties set forth in documents filed or to be filed with the Securities and Exchange Commission (the “SEC”) by the Company.
Establishing a new era of cognitive medicine through game-changing technologies Establishing a new era of congnitive medicine through game-chaning technologies
EDDIE MARTUCCI, PHD Chief Executive Officer, Co-Founder Former: PureTech Health MATT FRANKLIN President, Chief Operating Officer Former: Exact Sciences, Foundation Medicine, Boston Scientific JON DAVID Chief Product Officer Former: Microsoft, EA, Glu ANIL JINA, MD Chief Medical Officer Former: Pfizer, Sanofi, Shire, PPD CARL GOTTLIEB SVP, Engineering Former: eatsa, LendUp, Opower SANTOSH SHANBHAG Chief Financial Officer Former: Vertex Pharmaceuticals JACKIE STUDER Chief Legal Officer & General Former: GE Healthcare IT, Allscripts JULIE DICARLO SVP, Communications Former: Cubist, PureTech Health BARRIE BRIAN SVP, People Operations Former: TalentAction HRO MATT OMERNICK Chief Creative Officer, Co-Founder Former: LucasArts, EA, Microsoft
Brain function is the next frontier
2013 2016 2018 2020 2020 2022 0 0 0 0 0 0 In a landmark decision~ FDA greenlights a video game for kids with ADHD S AT+ I’Rf. 1st PATENT GRANTED FOR AKILI’S UNIQUE DTX MECHANISM Akili and Pfi z Akili study grabs atte t· . zer successfully with d’ · n ron gamlfy Afzheimer’s—0 DEPRESSION RCT IQJtal therapeutic f en RESULTS PUBLIS HE D adults with MOD a d or . TECHNOLOGY ~RERCE n new hrre S..r th z IN AJP 1--tS T UDIED AS ~ BioWorld.. SCREEN IN EARLY Q. ALZHEIMER’S >< 1ST TRIAL IN US w TARGETING COVID 0 BRAIN FOG TECHNOLOGY Doctors are testing a11COMM EN CED STUDIED AS A ..J . Vl’d 0 game for prescr\pt1on e MONITOR IN 0 ._.MULTIPLE u. COV\0-19 ‘brain fog .,., game-based EVO Monitor t- MULTIPLE SCLEROSIS AkI I S • . shows promise for cognttlve a: SCLEROSIS RCT 0 RESULTS PUBLIS HE . .,. JS t dy flfslWord screening 1n IYl : s u ttEALTHTECH Q. —-tiN NEUROLOGY AND THERAPY
eavor A First of its kind digital treatment delivered through a video game interface; currently being prescribed by physicians for pediatric patients with ADHD FDA indication: EndeovorRx® is a digital therapeutic indicated to improve attention function as measured by computer-based testing in children ages 8-12 years old with primarily inattentive or combined-type ADHD, who hove a demonstrated attention issue. Patients who engage with EndeovorRx® demonstrate improvements in a digitally assessed measure, Test of Variables of Attention (TOVA®), of sustained and selective attention and may not display benefits in typical behavioral symptoms, such as hyperactivity. EndeovorRx® should be considered for use as port of a therapeutic program that may include clinician-directed therapy, medication, and/or educational programs, which further address symptoms of the disorder. EndeovorRx® must be prescribed by a healthcore professional. It is not intended as a stand-alone therapeutic, nor is it a substitute for a child’s medication.
Current Akili pipeline: initial populations demonstrating potential breadth of technology 0 RESEARCH POC PIVOTAL COMMERCIAL Pediatric ADHD 8-12 y/o (US) Pediatric ADHD (EU) e e e CE SSME ~ Pediatric ADHD 6-17 y/o (Japan) 0 OG Pediatric ADHD 13-17 y/o (US) Adullt ADHD 18+ y/o (US) en w %—• Early childhood ADHD 3-8 y/o (US) 0 % w ..... Attention in autism spectrum disorder (ASD) (US) :J: ~ 0 Cognitive dysfunction in multiple sclerosis (MS) (US) LL ~ ~ SSMETM Cognitive dysfunction in depression (MDD) (US) Q. Acute cognitive dysfunction ( COVID, Post-ICU, CRCI) (US)—0 _______ . VANDE BILT Cognitive monitoring: screening and assessments 9 Q Phase completed POC = Proof of Concept
Recognition of cognitive function issues is at an all time high —--co~ ) experience adverse effects from medication2 up to up to of children have attention deficitsl of adults have cognitive impairments that may result in a decrease in independence and quality of life3 up to number of people with of adults experience cognitive dementia set to jump 40% to symptoms during depressive episodes4 by 20305 . Willcutt et al, Neurotherapeutics 9;490 (2012) . MTA Cooperative Group, Arch Gen Psychiatry 56;1073 (1999). Adverse event rate in drug treated arms of the mulitmodal treatment study of children with ADHD . Levere ete al, Curr Neural Neurosci Rep. 12;618 (2012) 10 . Conradi et al. Psychol Med. 2011;41(6):1165-74 . Dementia, Key Facts, WHO (Sep. 2, 2021).https://www.who.int/news-room/foct-sheets/detoil/dementia US populations only
Cognitive impairmen~ts exist across many medical conditions I B POLAR DISORDER TRAUMATC 8 R A N VASCULAR DISEASE ~PUS MCI J u R y SCHIZOPHRENIA c E 0 SENSO y PROCESSING DISORD R DYSLEX A HUNTINGTON’S DISEASE C R COY Y COVID BRAI OG 11
Current treatments and approaches are inadequate A new category of medicine Pharmaceuticals Physiologically-active DTx Behavioral therapy • Largely treats • MOA-based efficacy • Can lead to mixed results symptoms • Positive safety profile • Can have accessibility (vs. function) and cost issues • FDA clearance, Rx • Potential significant side effects DTx =Digital Therapeutics 12 MOA = Mechanism Of Action
Science & Product Devlopment 13
Akili has set the standard for clinical validation in digital medicine —--co~ TH L T igital Health syc Dig· al Peer-reviewed publications Cognitive dysfunction in ... ATTE TION DEF CIT HYPERACTIVITY DISORDER (ADHD) ALZHEIMER’S DISEASE (AD) AUTISM SPECTRUM DISO DE (ASD) SSMETM DEPRESSION (MOD) TM Selecfve Stimulus SSM Disease Clinica1l studies MILD COGNI IVE IMPAIRMENT (MCI) Management Engine completedl populationsl MULTIPLE SCLEROSIS (MS) SENSORY PROCESSING DISORDER (SPD) SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) TRAUMATIC BRAIN INJURY (TBI) Patients 14 lincludes research, proof of concept, and pivotal clinical studies
SSMETM is designed to target frontoparietal attention control networks —--co~ Attention Control: Capacity to apply necessary attention at appropriate time and place, while monitoring environment for new sources of information, to enable optimal processing of task-relevant information. A set of neural processes that allow us to interact with our complex environment in a goal-directed manner. ATTENTION EXECUTIVE FUNCTIONS FUNCTIONS FOCUS (Selective and sustained attention) !INTERFERENCE PROCESSING (Inhibition and conflict resolution) 1. Anguera et al. Nature 2013;501,97-101 2. Bavelier et al, Neuron 2019;104(1)147-163 3. McDowd et al, JNPT 2007;31(3)98-103 MULTITASKING (Divided attention) 4. Diamond et al, Ann Rev Psych 2013;64(1)135-168 15 5. Botvinick et al, Psychol Rev 2001;108(3)624
EndeavorRx® game mechanics overview SSME™ NAVIG A TION FOCUS Steer over gates and/or avoid obstacles INTERFERENCE PROCESSING T A R G E T I N G Tap for targets and ignore non-targets MULTITASKING M U LT I T A S K I N G Simultaneous navigation and targeting 16
Effects of SSME™on neural signatures of prefrontal attention control —--co Pre-SSME™ Post-SSM E™ Control Healthy older adults: enhanced midline frontal theta (MFT) power and fronta l-posterior theta coherence on EEGl Healthy older adults Healthy younger adults Children with sensory processing dysfunction and inattention: improvements in MFT power on EEG2 Children w/SP D + lA Typically developing child lale 7~ma I I 1 2 I I I I 1.0—pre—po5t Children with ADHD and attention symptoms: MFT changes between pre- and post-treatment on EEG3 iil 0..6 I I :E. t:: I I OA ~ 02 I I I I I I I ~—’ 0.0 1. Anguera et al. Nature 2013;501,97-101 I I I I I I I 2. Adapted from: Anguera et al. PJoS one, 2017;12(4), e0172616 -o.2 17 3. Gallen et al PLoS One 2021;16(12}: e0261981 0 ‘20 240 360 480 800 720 840 Sin Sl31’1 (M$)
Core technology advantage: closed-loop system SSME™ 18
Core technology advantage: population-tailored expansion/diï erentiation Core cognitive engine remains intact, while creating completely unique games tailored for each audience and personalized for each individual All games include the key SSME™ components yet are completely unique games designed for the audience Continuous, Visual discrimination SSME™ unpredictable motor task stimulus task Examples of Akili prototypes in development 19
Endeavor ADHD clinical studies —--co~ clinical trials children conducted with with ADHD Sensory Processing Autism Spectrum ADHD ADHD ADHD Disorder + ADHD Disorder + ADHD AKL-T01 (no meds) AKL-TOl (on meds) AKL-T01 AKL-T01 AKL-T026 Digital Control AKL-TOl (no meds) Healthy Control Healthy Control Digital Control! 12 weeks 4 weeks 4 weeks 4 weeks 4 weeks (4 on, 4 off, 4 on) 348 (348) 206 (206) 80 (40) 57 (20) 19 (19) 8-12 yrs 8-14 yrs 8-12 yrs 9-12 yrs 9-15 yrs 1 Kollins et al, Lancet Digital Health, 2020 2(4) 4 Anguera et al, PLoS One. 2017;12(4):1-19 2 Kollins et al, Nature Digital Medicine (2021)4:58 s Yerys et al, J Autism Dev Disord. 2019;49(4):1727-1737 20 3 Davis et al, PLoS One, 2018, 13(1): e0189749 6AKL-T02, while retaining the same user interface and SStv1E therapeutic engine as AKL-TOl, has adapted gameplaydifficulty intended to increase user engagement in an autism spectrum disorder population.
ADHD clinical studies —--co~ THE LAI\CET STARS STUDY ADJUNCT STUDY na11 Digital Health PRIMARY ENDPOINT PRIMARY ENDPOINT Digital Medicine p::0.006 First Treatment Second Treatment 40 Period Period—r:: f- -1 f--—--1 cu 1.0 E • SSME only (n=76) ~ • SSME (both cohorts) ew • SSME+stimulants (n=130) 0. Cl) 35 ·r::—0.75 _e, m cu—+ B c r:: ~ g 0 0.50 .t::. Cl) :l: 30 — u ~— w 6 ~ J: 0.25 c c ~ 25 0 cu Treatment Pause ~ 0 _..__ BL 28 56 84 AKL-T01 Control N=169 =160 Days Significant improvement in ADHD symptom and impairment objective attention compared improvement sustained after 1st to matched controll treatment, increased after 2nd treatment, and similar with or without medications2 No Serious Adverse Events’s (AE’s) in any study. All AE’s mild in nature. SAFETY & 0 8 1 1 T L ERA L T Y Total AE’s across studies3: 9.3%: decreased frustration tolerance: (6.1%), headache: (1.3%), irritability, dizziness, nausea: (all <1%) l . Kollins et al, Lancet Dig Hlth 2020; 2(4): PEl68-El78 2. Koll ns et al, NPJ Dig Med, 2021;4:58 21 3. EndeavorRx IFU
EndeavorRxTM treatment of—responder rates across studiesl,2 —--co~ % children moving into normative range in at least one 36% — objective measure of attention % Children with >1-point improvement 48% 50% 68% % Children with ~30% improvement 24% 27% 45% “Do you think playing the app improved your child’s 56%—60% ability to pay attention?” %YES “Do you think playing the app improved your ability to 73%—75% pay attention?” %YES I Kollins et al, Lancet Digital Health, 2020 2(4), e168-e178 2 Koflins et a/, Nature Digital Medicine (2021)4:58 22
ADHT Market EndeavoRx Commerical Launch 23
Pediatric ADHDl % of children with ADHD spend per ADHD child vs. have attention deficits neurotypical child % patients tried/trying/plan to try not currently on or well-non-pharmacological treatments controlled by medication Willcutt (2012) Neurotheropeutics, 9(3): 490-499; additudemag.com/ 24 cost-of-raising-adhd-child-study/; 2017 Clarion primary market research
EndeavorRx® has a large and attractive initial target population in addressing attention issues ADHD MARKET3—US ONLY (patients in millions) 11M Current prescription ADHD treatments in the US address large patient populations 4.7M 8M ADULT $ 1 ~ 10Bn 3.3M A D U LT ADHD MARKET 2.8M AG E S 1 3—1 7 1.9M A G E S 1 3—1 7 2 I N I T I A L I N D I C A T I O N >70M 2.1M 1.8M A G E S 8—1 2 FDA C L E A R E D A G E S 8—1 2 Prescriptions per year 1.2M 1.1M A G E S 3—8 A G E S 3—8 Total market Initial target population in inattention 1. DelveInsight, ADHD Market Insights, Epidemiology and Market Forecast-2027 (Dec. 2018) 260 25 2. 2020 IMS Data 3. please see slide #36 for sources
® eavor A First of its kind digital treatment delivered through a video game interface; currently being prescribed by physicians for pediatric patients with ADHD FDA indication: EndeovorRx® is a digital therapeutic indicated to improve attention function as measured by computer-based testing in children ages 8-12 years old with primarily inattentive or combined-type ADHD, who hove a demonstrated attention issue. Patients who engage with EndeovorRx® demonstrate improvements in a digitally assessed measure, Test of Variables of Attention (TOVA®), of sustained and selective attention and may not display benefits in typical behavioral symptoms, such as hyperactivity. EndeovorRx® should be considered for use as port of a therapeutic program that may include clinician-directed therapy, medication, and/or educational programs, which further address symptoms of the disorder. EndeovorRx® must be prescribed by a healthcore professional. It is not intended as a stand-alone therapeutic, nor is it a substitute for a child’s medication.
Endeavor “””——‘1N SIGHT A • Companion App for Caregivers Tracking Progress Today Provides caregivers with a daily snapshot of their child’s in-game progress. Jul 22 Compliance All Room to missions Caregivers can follow along with their child’s effort and level completion. improve played! Support Caregivers can connect with Akili Assist® experts if they need help. This Week Jul 19 • Jul 25 Mon Tue Wed Too Fri Sot Sun 27
EndeavorRx® distribution model is live —--co~ HCP PRESCRIBES ENDEAVORRX Through PhiiRx to complete IN-PERSON fulfillment VISIT WITH HCP OR TELE-HEALTH VISIT WITH HCP to discuss EndeavorRx as treatment option AKILI ASSIST is committed to supporting caregivers along the journey through our Nurse Navigators PHIL DISPENSES and other helpful resources to address questions about Benefits investigation, payment, EndeavorRx treatment. and activation ACTIVE TREATMENT HCP FOLLOWS UP Child engages with EndeavorRx; to understand child’s progress in caregivers can monitor in-game progress improving attention, in combination ® through EndeavorRx Insight app with other therapies Endeavor 28 HCP: Healthcare Professional
Commercialization model —--co~ Customer-driven model Prescription-therapeutic, hybrid self-pay reimbursement model. Catalyzed by activated consumers (parents unsatisfied with current treatment options) and efficient HCP education and e-prescribing Frictionless Delivery Option for patient doctor or streamlined telemedicine consult; Mobile-first Rx adjudication and rapid prescription activation, with seamless re-fill process Data-rich Care Program Rich data allows personalized support through Akin Assist customer service, targeted communications, and companion applications (e.g., EndeavorRx Insight) for caregivers to track & monitor treatment progress ® Endeavor 29
EndeavorRx®—key drivers of the model P H A S E PRE-LA UNCH PRE-LA UNCH P R E—L A U N C H PRE-LA UNCH G R O W T H M E T R I C F Y 2 0 2 1 Q 1 ’ 2 2 Q 2 ’ 2 2 V S . Q 2 ’ 2 1 Total Rx Written 1,713 668 772 140% D E M A N D New Rx 1,422 503 602 102% Refill Rx 291 165 170 608% Total Prescribers 877 437 480 109% ENG A GEMENT New Prescribers 833 239 274 36% Conversion (Written To Dispensed)* 44% 39% 52% — % of TRx Self Paid 86% 89% 93% — % of TRx Reimbursed 10% 4% 3% — REIMB UR SEMENT ASP (excl. Patient Assistance Program) $308 $297 $109 (66%) Total Covered Lives 2.8M 2.6M 2.6M — * conversion metric updated two reflect written to disposed versus prior reported enrolled to dispensed 30
Financial Overview
Expected ADHD label expansion INITIAL TARGET POPULATION SIZE2 (patients in millions) ADHD MARKET—US ONLY T O T A L 8 . 1 1 . 1 POC start: H1 ’23 4 3—7 Y E A R—O L D $ 3 . 3 Pivotal data: H2 ’23 E 3 A D U LT U N E V E R 1 . 9 Pivotal data: H2 ’23 2 1 3—1 7 Y E A R—O L D FDA 1 . 8 CLEARED 1 8 – 1 2 Y E A R—O L D Launch: H2 ‘22 T I M E 1 1. Timeframes are estimates and are subject to change—see Disclaimer and Risk Factors 2. please see slide #36 for sources 32
$500M+ Revenue potential in the US in 5-7 yrs in ADHD alone $500M+ per yr. US ADHD revenues (estimated in 5-7 yrs) Upside potential: • Additional payor coverage over-time reduces % of $300M $200M self-pay 1.5 Rx refills per patient after 1st Rx • Reduced gross-to-net discounting ~15% gross-to-net discount (based on current distribution structure) • Ability to adapt treatment through the patient’s life extending revenue tail WAC / Rx Cash Price / Rx $450 $295 • No patent cliffs typically associated with drugs 50% patients via 50% patients via insurance reimbursement self-pay Additional revenue opportunities: ~325,000 ~325,000 • Supplemental revenue model potential for services or ~650K Patients Treated treatment maintenance (e.g., care-team connected companion apps like EndeavorRx Insight®) 8% base market penetration for model (as a reference, non-stimulants ~10%1, behavioral therapy ~47%2) • Potential for physician reimbursement through 8.1M Target Population1 remote patient monitoring excludes hyperactive only patients ~11M US ADHD Market1 Represents market penetration of other products 1. please see slide #36 for sources 33 2. CDC.gov
Current Akili pipeline: initial populations demonstrating potential breadth of technology 0 ESTIMATEDl NEXT MILESTONE TIME IFRAME Pediatric ADHD 8-12 y/o (US) Launch H2 ‘22 Pediatric ADHD (EU) Launch —SSMETM Pediatric ADHD 6-17 y/o (Japan) s 10 oo Pivotal trial data H2 ‘23 en Pediatric ADHD 13-17 y/o (US) Pivotal trial data H2 ‘23 w z C)—Adult ADHD 18+ y/o (US) Pivotal trial data H2 ‘23 z w ....... Early childhood ADHD 3-8 y/o (US) Initiate pilot study Hl ‘23 :1: ~ 0 II. Attention in autism spectrum disorder (ASD) (US) Pre-pivotal trial meeting (FDA O·sub) H2 ‘22 1- ~ ..J Q. Cognitive dysfunction in multiple sclerosis (MS) (US) Pre-pivotal trial meeting (FDA 0-sub) Hl ‘23 SSME TM Cognitive dysfunction in depression (MDD) (US) Pre-pivotal trial meeting (FDA O·sub) H2’23 Acute cognitive dysfunction (COVID, Post-ICU, CRCI) (US) COVID fog pilot study data H2 ‘22 Cognitive monitoring: screening and assessments Initiate pivotal study H2 ‘23 + 34 1. Timeframes are estimates and are subject to change- see Disclaimer and Risk Factors
Thank you Contact: Santosh Shabhag sshabhag@akilinteractive.com
Sources supporting slides Disease Area Source of Total Population Source for calculations supporting Initial Target Population
ADHD4·7 CDC Survey Estimates, 2014 National Survey on Children’s Health (CDC); 2003-2011 ADHD 8-12 Danielson (2018) J Clin Child Adoles Psychol., 47(2): 199-212 Willcutt (2012) Neurotherapeutics, 9(3): 490-499 ADHD 13-17 Danielson (2018)
J Clin Child Adoles Psychol., 47(2): 199-212 Willcutt (2012) Neurotherapeutics, 9(3): 490-499 Raman (2018) Lancet Psychiatry, 5(10): 824-835.; Fayyad (2007) Br J Psychiatry. 190: ADHD Adult Salvi et al. Riv Psichiatr. Mar-Apr 2019;54(2) 402-409 ADHD
EU Clarion EU & Japan Population Estimates Willcutt (2012) Neurotherapeutics, 9(3): 490-499 ADHD JP Clarion EU & Japan Population Estimates Shionogi partner estimates Baio, J.et al MMWR Surveillance Summary (2018) Autism
https://www .cdc.gov/ncbddd/autism/data.html
Rommelse et al. 2010. Eur Child Adolesc
Psychiatry: 2016 NSDUH survey Conradi HJ, Ormel J, de Jonge P. Presence of individual (residual) symptoms during Depression (MOD)
https://www
..nimh.nih.gov/health/statistics/majordepression
depressive episodes and periods of remission: a 3-year prospective study. Psychol Med 2011;41(6):1165-74 Landmark
Study Estimates Nearly 1 Million in the U.S. Have Multiple Sclerosis, Multiple Sclerosis National MS Society (Feb. 15, 2019)
https://www .nationalmssociety.org/
About the Benedict et al. BMC Neural. 2012;12:55 Society/News/Landmark StudyEstimates-Nearly%c2%a01 Million in the U See combined sources for COVID fog,
cancer-related cognitive impairment, TBI, and ICU related Acute Cognitive Dysfunction cognitive dysfunction
https:LLwww.(ublichealth.columbia.edu
public health nowLnewsLone three americans a lready had covid-19-end-2020 COVID Fog Garriges et al., 2020, Journal of Infection, Helm et al., 2020, The New England Taquet et al
2021 PLOS Medicine Journal of Medicine; Jaywant et al., 2021, Neuropsychopharmacology, Kaseda et al., 2020, The Clinical Neuropsychologist; Rogers et al., 2020, Lancet Psychiatry Cancer-Related
https://www .cdc.gov/cancer/preventinfections/providers.htm
Jaelsins et al. 2018 Journal of
Clinical Oncology Cognitive Impairment https://www .cancer.gov/about-cancer/understanding-chemobrain Fiden et al Centers for Disease Control and Prevention. (2015). Report to Congress on Traumatic Brain Injury in the United States: Epidemiology and
Rehabilitation. ... Traumatic Brain Injury National Center for Injury Prevention and Control; Division of Unintentional Rabinowitz & Levin 2014 Cognitive Sequelae of Traumatic Brain Injury https://www.cdc.govLtraumaticbraininjuryL(dfLtbi re(ort
to congress e( and rehaba.df
https://www .sccm.org/Communications/Criticai-Care-Statistics ICU-Related Cognitive Dysfunction https://www
..sccm.org/Communications/Criticai-Care-Statistics Cavallazzi et al 2012. Annals of Intensive Care 36
APENDIX Clinical Date
Autism spectrum disorder (ASD) 1.3M 410K TOT A L TA R G E T Children with ASD are at high risk for impairments in attention function1 The presence of ADHD symptoms in children with autism spectrum disorder is associated with worse cognitive (attention) control1 Attention impairments contribute to poor functional outcomes, such as reduced adaptive behavior1 Pilot study (n=18), demonstrated high acceptability and engagement with SSME and an improvement in attention and ADHD outcome measures compared to a control condition a er 4 weeks of treatment1 ST A T U S PRE-PIV O T A L T R I A L M E E T I N G ( F D A Q—S U B ) : E S T I M A T E D H 2 2 0 2 2
Multiple sclerosis (MS) PA T I E N T S U S 4 900K 180K TOT A L TA R G E T Incidence of cognitive dysfunction in MS ranges from 20-60%1 7 SSME (n=20) Control (n=20) 6 It is predictive of loss of employment, loss of quality of life, and aïects all aspects of daily life1 5 baseline) clinically meaningful 4 change Pilot study (n=21), significant improvement in processing SDMT from 3 speed (SDMT) in patients with cognitive dysfunction in MS2 2 (change 3.0 1 POC RCT (n=40), clinically significant improvement in SDMT (>4) aï…er 6 weeks treatment (vs. baseline) with 0 SSME™ in patients with cognitive dysfunction in MS. 70% of 6 weeks Rx 14 weeks f/u patients randomized to SSME™ maintained this clinically ™ SSME not statistically significant vs. control Adapted from: Bove et al MS Jour 2020; 27(5);778-789 meaningful 4+ point increase in SDMT aï…er a further 8 weeks observation period (compared with 37% for control, p = 0.038)3 1. Benedict et al. BMC Neurol. 2012;12:55 2. Bove et al Neurol Ther 2019;8(1):135–145 3. Bove et al MS Jour 2020; 27(5);778-789 ST A T U S PRE-PIV O T A L T R I A L M E E T I N G ( F D A Q—S U B ) : E S T I M A T E D H 1 2 0 2 3 4. please see slide #36 for sources 39 Timeframes are estimates and are subject to change—see Disclaimer and Risk Factors
Major depressive disorder (MDD) PA T I E N T S U S 4 19M 2.1M TOT A L TA R G E T Cognitive symptoms are present during up to 94% of 5 SSME (n=37) depressive episodes and up to 44% of periods of 4 Control (n=37) remission1 3 2 Serious impact on patients’ quality of life and activities of ention 1 daily living1 tt H1) 0 A -1 (TOVA -2 Inter-episode cognitive function is related to the number of -3 previous depressive episodes2 Sustained -4 -5 POC RCT (n=74), significant improvement in measures of -6 attention aſter 6 weeks treatment with SSME compared to -7 Adapted from: Keefe et al AJP (2022) control3 1. Conradi et al. Psychol Med. 2011;41(6):1165–74 2. Kessing et al Psychol Med. 1998;28(5):1027–38 3. Keefe et al AJP (2022) ST A T U S PRE-PIV O T A L T R I A L M E E T I N G ( F D A Q—S U B ) : E S T I M A T E D H 2 2 0 2 3 4. please see slide #36 for sources 40 Timeframes are estimates and are subject to change—see Disclaimer and Risk Factors
Acute cognitive dysfunction PA T I E N T S US 2 81M 700KTBI 1.3MCOVID 1MCHEMO 300KICU TOT A L TA R G E T Cognitive impairments can occur aï…er acute insults to the brain due to trauma, infection, hypoxia, inflammation, medication, toxins, critical illness, cancer etc. 0.4 SSME (n=28) Control (n=28) No Game (n=28) SSME™ has the potential to assist in the short- and long- 0.3 term cognitive rehabilitation of these patients score) 0.2 Pilot study (n=84) completed in chronic TBI (veterans 60-85 yrs with history of multiple mild TBIs or ≥1 moderate TOVA 0.1 TBI and subjective cognitive complaints) showed significant composite improvement in measures of attention (reaction time) and 0 working memory compared to controls1 ention tt -0.1 2 separate collaborative studies (n = 100 each) with Weill (a Cornell Medicine, NewYork-Presbyterian Hospital and -0.2 Vanderbilt University Medical Center underway in cognitive 4 weeks Rx 12 weeks f/u dysfunction following Covid infection (Covid Fog). Both investigate the eïects of SSME (AKL-T01) over 4 or 6 weeks 1. Kaup et al. AAIC 2019, A&D 15(7S);5;253-254 treatment compared to a TAU control group. ST A T U S CO V I D F O G P I L O T S T U D Y D A T A : E S T I M A T E D H 2 2 0 2 2 2. please see slide #36 for sources 41 Timeframes are estimates and are subject to change—see Disclaimer and Risk Factors
Cognitive monitoring Cognition is oï…en only assessed when there is a specific, subjective complaint from patients, family members, or caregivers1 There is no consistent clinical protocol for how to use cognitive assessment tools1 Most cognitive assessments have not changed in decades and many are still performed on pen and paper1 Pilot study in MS (n=100) showed positive correlation between recognized cognitive function measure (SDMT) and SSME in assessing cognition2 Pilot study in older adults (n=54) showed ability of SSME™ to detect cognitive diïerences between amyloid +/- 1. Smith et al Psych Times July 2021 patients3 2. Hsu et al. JMIR 2021;23(1) 3. Leurent et al, CTAD 2016, JPAD 3;S1;280-281 ST A T U S O N G O I N G S T U D I E S—A D H D , A G I N G ; P L A N N E D : I N I T I A T E P I V O T A L S T U D Y E S T I M A T E D H 2 2 0 2 3 + 42 Timeframes are estimates and are subject to change—see Disclaimer and Risk Factors
R&D technologies: beyond SSME Priority areas of study: Alzheimers, MCI (mild cognitive impairment) SNAV™ Spatial Navigation Engine S P A T I A L N AV I G A T I O N , E P I S O D I C M E M O R Y BBT ™ Body Brain Trainer AT T E N T I O N , G O A L M A N A G E M E N T , W O R K I N G M E M O R Y 43